DCLRE1A and cancer: The reasons for this require further investigation with one possibility being additive effects of SNM1A inhibition and underlying defects in the machinery maintaining genome stability in cancer cells, and/or the presence of more robust cell cycle checkpoints in non-cancer cells preventing unrestrained entry into S-phase in the presence of cisplatin damage.